Australia markets closed

I-Mab (IMAB)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.7600-0.0050 (-0.28%)
At close: 04:00PM EDT
1.7600 0.00 (0.00%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7650
Open1.8100
Bid1.3200 x 200
Ask2.2700 x 200
Day's range1.7600 - 1.8300
52-week range1.1600 - 3.4500
Volume126,330
Avg. volume347,658
Market cap142.354M
Beta (5Y monthly)1.11
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    I-MAB Filed 2023 Annual Report on Form 20-F

    I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.

  • PR Newswire

    I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

    I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

  • PR Newswire

    I-Mab Announces Closing of the Divestiture of Business Operations in China

    I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the "Transaction") have been either satisfied or waived and accordingly, the Transaction has successfully closed.